National Guideline Clearinghouse | Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.

full-text ►

National Guideline Clearinghouse | Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.



National Institute for Health and Care Excellence (NICE)

Guideline Title

Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma.

Bibliographic Source(s)

National Institute for Health and Care Excellence (NICE). Dabrafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma. London (UK): National Institute for Health and Care Excellence (NICE); 2014 Oct. 36 p. (Technology appraisal guidance; no. 321).

Guideline Status

This is the current release of the guideline.

This guideline meets NGC's 2013 (revised) inclusion criteria.